BRD2 and cryohydrocytosis: In collaboration with the investigators of the NeoOPTIMIZE clinical trial (NCT04539808), which studies the efficacy of adaptive NAT regimens for those with localized PDAC, we prospectively and longitudinally evaluated CHC numbers in eight patients and temporally correlated CHC numbers to treatment with NAT and ultimate pathologic response following pancreatectomy (Figure 4).